Skip to main content
SpringerLink
Log in

Leitlinien Insulinpumpentherapie bei Kindern und Erwachsenen (Für den Ausschuss Insulinpumpentherapie der Österreichischen Diabetesgesellschaft)

Guidelines for insulin pump therapy in children and adults

  • leitlinien für die praxis
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Dieses Positionspapier zur Anwendung der subkutanen Insulinpumpentherapie (CSII) bei Diabetes mellitus basiert auf aktueller Evidenz zu Sicherheit und Vor-und Nachteile der CSII, insbesondere im Hinblick auf glykämische Kontrolle, Hypoglykämie, ketoazidotische Entgleisung, Lebensqualität und Anwendung in der Schwangerschaft. Dieser Artikel beinhaltet die Empfehlungen der Österreichischen Diabetesgesellschaft für die klinische Anwendung der Insulinpumpentherapie bei Kindern und Erwachsenen.

Summary

This position statement is based on the cur­rent evidence available on the safety and benefits of continous subcutaneous insulin pump therapy (CSII) in diabetes mellitus with an emphasis on the effects of CSII on glycemic control, hypoglycaemia rates, occur­ance of ketoacidosis, quality of life and the use of insu­lin pump therapy in pregnancy. The current article rep­resents the recommendations of the Austrian Diabetes Association for the clinical praxis of insulin pump treat­ment in children and adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:361–76.

  2. Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care. 1998;21:817–21.

    Article  PubMed  CAS  Google Scholar 

  3. Bachran R, Beyer P, Klinkert C, Heidtmann B, Rosenbauer J, Holl RW. Basal rates and circadian profiles in continuous subcutaneous insulin infusion (CSII) differ for preschool children, prepubertal children, adolescents and young adults. Pediatr Diabetes. 2012;13:1–5.

    Article  PubMed  CAS  Google Scholar 

  4. Bending JJ, Pickup JC, Keen H. Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Audit of medical care. Am J Med. 1985;79:685–91.

    Article  PubMed  CAS  Google Scholar 

  5. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–20.

    Article  PubMed  CAS  Google Scholar 

  6. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011;34:2403–5.

    Article  PubMed  Google Scholar 

  7. Berghaeuser MA, Kapellen T, Heidtmann B, Haberland H, Klinkert C, Holl RW. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes. 2008;9:590–595.

    Article  PubMed  CAS  Google Scholar 

  8. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care. 1996;19:324–7.

    Article  PubMed  CAS  Google Scholar 

  9. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care. 1999;22:1779–84.

    Article  PubMed  CAS  Google Scholar 

  10. Chantelau E, Schiffers T, Schutze J, Hansen B. Effect of patient-selected intensive insulin therapy on quality of life. Patient Educ Couns. 1997;30:167–73.

    Article  PubMed  CAS  Google Scholar 

  11. Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia. 1989;32:421–6.

    Article  PubMed  CAS  Google Scholar 

  12. Chen R, Ben Haroush A, Weismann-Brenner A, Melamed N, Hod M, Yogev Y. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol. 2007;197:404–5.

    PubMed  Google Scholar 

  13. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290:811–5.

    Article  CAS  Google Scholar 

  14. Danne T, Battelino T, Jarosz-Chobot P, Kordonouri O, Pankowska E, Ludvigsson J, Schober E, Kaprio E, Saukkonen T, Nicolino M, Tubiana-Rufi N, Klinkert C, Haberland H, Vazeou A, Madacsy L, Zangen D, Cherubini V, Rabbone I, Toni S, de BC, Bakker-van WW, Van Den Berg N, Volkov I, Barrio R, Hanas R, Zumsteg U, Kuhlmann B, Aebi C, Schumacher U, Gschwend S, Hindmarsh P, Torres M, Shehadeh N, Phillip M. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries. Diabetologia. 2008;51:1594–1601.

    Article  PubMed  CAS  Google Scholar 

  15. Danne T, von Schüz W, Lange K, Nestoris C, Datz N, Kordonouri O. Current practice of insulin pump therapy in children and adolescents -- the Hannover recipe. Pediatr Diabetes. 2006;7(Suppl 4):25–31.

    Article  PubMed  Google Scholar 

  16. Devries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002;25:2074–80.

    Article  PubMed  CAS  Google Scholar 

  17. Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2007;18(3):CD005542.

    Google Scholar 

  18. Gabbe SG, Holing E, Temple P, Brown ZA. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol. 2000;182:1283–91.

    Article  PubMed  CAS  Google Scholar 

  19. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care. 2000;23:1232–5.

    Article  PubMed  CAS  Google Scholar 

  20. Hanas R, Lindgren F, Lindblad B. A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use. Pediatr Diabetes. 2009;10:33–7.

    Article  PubMed  Google Scholar 

  21. Hermanides J, Norgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, Diem P, Fermon C, Wentholt IM, Hoekstra JB, Devries JH. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med. 2011;28:1158–67.

    Article  PubMed  CAS  Google Scholar 

  22. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28:533–8.

    Article  PubMed  Google Scholar 

  23. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, Siebenhofer A. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51:941–51.

    Article  PubMed  CAS  Google Scholar 

  24. Jones SM, Quarry JL, Caldwell-McMillan M, Mauger DT, Gabbay RA. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol Ther. 2005;7:233–40.

    Article  PubMed  CAS  Google Scholar 

  25. Kernaghan D, Farrell T, Hammond P, Owen P. Fetal growth in women managed with insulin pump therapy compared to conventional insulin. Eur J Obstet Gynecol Reprod Biol. 2008;137:47–9.

    Article  PubMed  CAS  Google Scholar 

  26. Klupa T, Benbenek-Klupa T, Malecki M, Szalecki M, Sieradzki J. Clinical usefulness of a bolus calculator in maintaining normoglycaemia in active professional patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. J Int Med Res. 2008;36:1112–6.

    PubMed  CAS  Google Scholar 

  27. Knight G, Jennings AM, Boulton AJ, Tomlinson S, Ward JD. Severe hyperkalaemia and ketoacidosis during routine treatment with an insulin pump. Br Med J (Clin Res Ed). 1985;291:371–2.

    Article  CAS  Google Scholar 

  28. Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, Lange K, Knip M, Danne T. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia. 2010;53:2487–95.

    Article  PubMed  CAS  Google Scholar 

  29. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.

    Article  PubMed  CAS  Google Scholar 

  30. Mecklenburg RS, Benson EA, Benson JW Jr., Fredlund PN, Guinn T, Metz RJ, Nielsen RL, Sanner CA. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA. 1984;252:3265–9.

    Article  PubMed  CAS  Google Scholar 

  31. Mecklenburg RS, Guinn TS. Complications of insulin pump therapy: the effect of insulin preparation. Diabetes Care. 1985;8:367–70.

    Article  PubMed  CAS  Google Scholar 

  32. Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD005103.

  33. Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol. 2007;197:447–56.

    Article  PubMed  CAS  Google Scholar 

  34. Nuboer R, Borsboom GJ, Zoethout JA, Koot HM, Bruining J. Effects of insulin pump vs. injection treatment on quality of life and impact of disease in children with type 1 diabetes mellitus in a randomized, prospective comparison. Pediatr Diabetes. 2008;9:291–6.

    Article  PubMed  Google Scholar 

  35. O’Connell MA, Gilbertson HR, Donath SM, Cameron FJ. Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy: impact of glycemic index and prandial bolus type. Diabetes Care. 2008;31:1491–5.

    Article  PubMed  Google Scholar 

  36. Pankowska E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009;10:52–8.

    Article  PubMed  CAS  Google Scholar 

  37. Peyrot M, Rubin RR. Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: the Insulin Delivery System Rating Questionnaire. Diabetes Care. 2005;28:53–8.

    Article  PubMed  Google Scholar 

  38. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25:593–8.

    Article  PubMed  Google Scholar 

  39. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705.

    Article  PubMed  CAS  Google Scholar 

  40. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765–74.

    Article  PubMed  CAS  Google Scholar 

  41. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003 26:2598–2603.

    Article  PubMed  CAS  Google Scholar 

  42. Retnakaran R, Hochman J, Devries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care. 2004;27:2590–6.

    Article  PubMed  CAS  Google Scholar 

  43. Reznik Y, Morera J, Rod A, Coffin C, Rousseau E, Lireux B, Joubert M. Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up. Diabetes Technol Ther. 2010;12:931–6.

    Article  PubMed  CAS  Google Scholar 

  44. Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes. 2008;9:472–9.

    Article  PubMed  CAS  Google Scholar 

  45. Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 2012;13:6–11.

    Article  PubMed  CAS  Google Scholar 

  46. Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care. 2001;24:1722–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenskonflikt

M. S. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten:Medtronic, Novo Nordisk, Roche, sanofi-aventis.

S. Z. F. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Astra Zeneca, Bayer Health Care, GlaxoSmithKline Pharma, Johnson&Johnson Medical, Eli Lilly, Medtrust, Medtronic, Merck Serono, Merck Sharp&Dohme, Novartis, Novo Nordisk, Pfizer, Roche, sanofiaventis, Servier, Takeda.

I. Sch.-F. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten:Bayer Health Care, Medtronic, Roche, Eli Lilly, Medtrust, Novo Nordisk, sanofi-aventis.

B. R.-M. hat in den letzten 36 Monaten von folgenden Firmen Honorare/Forschungsgelder erhalten: Bayer Health Care, Eli Lilly, Medtronic, Novo Nordisk, sanofi-aventis, Takeda.

E. S. hat in den letzten 36 Monaten von folgenden Firmen Honorare/Forschungsgelder erhalten: Medtronic, Novo Nordisk, sanofi-aventis.

A. K. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Astra Zeneca, Bayer Health Care, Bristol-Myers Squibb, GlaxoSmithKline Pharma, Eli Lilly Merck Sharp&Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis

R. W. hat von folgenden Unternehmen, die teils auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Astra Zeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Germania Pharmazeutika,GlaxoSmithKline Pharma,Eli Lilly, Medtronic, A.Menarini, Merck Serono, Merck Sharp&Dohme, Novartis, Novo Nordisk, Roche, sanofi, Servier, Takeda.

R. P. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott, Astra Zeneca, Bristol-Myers Squibb, Johnson&Johnson Medical, Eli Lilly, Merck Sharp&Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis, Takeda.

M. B. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Eli Lilly, Medtrust, Medtronic, Novartis, Novo Nordisk, Roche, sanofi‐aventis, Smiths Medical.

Author information

Authors and Affiliations

  1. 3. Medizinische Abteilung für Stoffwechselerkrankungen und Nephrologie, Krankenhaus Hietzing, Wien, Österreich

    Marietta Stadler, Ingrid Schütz-Fuhrmann & Rudolf Prager

  2. Karl Landsteiner Institut für Stoffwechselerkrankungen und Nephrologie, Wien, Österreich

    Marietta Stadler & Rudolf Prager

  3. 1. Medizinische Abteilung, Landeskrankenhaus Klagenfurt, Klagenfurt, Österreich

    Sandra Zlamal-Fortunat

  4. Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Wien, Österreich

    Birgit Rami-Merhar & Edith Schober

  5. Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich

    Alexandra Kautzky-Willer

  6. Abteilung für Innere Medizin, Diakonissen-Krankenhaus, Salzburg, Österreich

    Raimund Weitgasser

  7. Universitätsklinik für Innere Medizin I, LKH Salzburg – Universitätsklinikum, Paracelsus Medizinische Privatuniversität, Salzburg, Österreich

    Raimund Weitgasser

  8. Krankenhaus St. Elisabeth, Wien, Österreich

    Martin Bischof

Authors
  1. Marietta Stadler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra Zlamal-Fortunat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ingrid Schütz-Fuhrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Birgit Rami-Merhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edith Schober
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexandra Kautzky-Willer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raimund Weitgasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rudolf Prager
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Martin Bischof
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marietta Stadler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stadler, M., Zlamal-Fortunat, S., Schütz-Fuhrmann, I. et al. Leitlinien Insulinpumpentherapie bei Kindern und Erwachsenen (Für den Ausschuss Insulinpumpentherapie der Österreichischen Diabetesgesellschaft). Wien Klin Wochenschr 124 (Suppl 2), 123–128 (2012). https://doi.org/10.1007/s00508-012-0287-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-012-0287-x

Schlüsselwörter

Keywords

Search

Navigation